Ann Allergy Asthma Immunol 2021 Jun 6. Epub 2021 Jun 6.
Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address:
Cutan Ocul Toxicol 2021 Jul 2:1-7. Epub 2021 Jul 2.
Department of Dermatology, Koc University School of Medicine, Istanbul, Turkey.
Background: Omalizumab is an effective and safe treatment for antihistamine resistant chronic spontaneous urticaria (CSU), however, long-term efficacy and safety remains unclear.Objective: To evaluate the efficacy and safety of omalizumab in CSU patients treated for long term and to identify long-term management strategies.Methods: We retrospectively analyzed demographic characteristics, clinical features, laboratory parameters and treatment outcomes of 41 CSU patients who received omalizumab for at least 3 years. Read More
Curr Treat Options Allergy 2021 Apr 16:1-13. Epub 2021 Apr 16.
Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD USA.
Purpose Of Review: Studies show that inhibitors of Bruton's tyrosine kinase (BTKis), currently FDA-approved for the treatment of B cell malignancies, can prevent IgE-mediated reactions through broad inhibition of the FcεRI signaling pathway in human mast cells and basophils. This review will summarize recent data supporting the use of these drugs as novel therapies in various allergic disorders.Recent Findings: Recent studies have shown that BTKis can prevent IgE-mediated degranulation and cytokine production in primary human mast cells and basophils. Read More
Clin Exp Allergy 2021 Apr 18. Epub 2021 Apr 18.
David Hide Asthma and Allergy Research Centre, Isle of Wight, UK.
Background: Omalizumab and Mepolizumab are biologic drugs with proven efficacy in clinical trials. However, a better understanding of their real-world effectiveness in severe asthma management is needed.Objectives: To better understand the real-world effectiveness of Omalizumab and Mepolizumab, elucidate the clinical phenotypes of patients treated with these drugs, identify baseline characteristics associated with biologic response and assess the spectrum of responses to these medications. Read More
Biomedicines 2021 Mar 30;9(4). Epub 2021 Mar 30.
Pneumology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.
Viral respiratory infections are recognized risk factors for the loss of control of allergic asthma and the induction of exacerbations, both in adults and children. Severe asthma is more susceptible to virus-induced asthma exacerbations, especially in the presence of high IgE levels. In the course of immune responses to viruses, an initial activation of innate immunity typically occurs and the production of type I and III interferons is essential in the control of viral spread. Read More